The operating theater blood transaction system (OTBTS) is a virtual blood banking system that allows computer crossmatch-compatible blood ordering and delivery in the operating theater remote from the hospital blood bank. It was developed and implemented in our hospital in 1997 and was expanded in 2002 to include an unmatched blood module that allows ordering and issuing unmatched RBCs for intraoperative transfusion. During the past 7 years, the system has handled 6,333 crossmatch requests for intraoperative transfusion and issued 20,073 units of RBCs, including 100 units of unmatched RBCs (group O, 72 units; group-identical, 28 units). The OTBTS has proven to be efficient (with a turnaround time for blood ordering and issuing < 30 seconds), effective (with a reduced crossmatch/transfusion ratio and blood wastage), and error free (no delay or error in transfusion or postponement of operation). Furthermore, our experience with the unmatched blood module has attested to the safety and efficacy of computer-controlled, online ordering and real-time, on-site delivery of unmatched RBCs for emergency transfusion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1309/13CUJ61YRB50B1CT | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Standard Compared With Extended Red Blood Cell Antigen Matching for Prevention of Subsequent Hemolytic Disease of the Fetus and Newborn: A Systematic Review.
Obstet Gynecol
October 2024
Department of Obstetrics and Gynecology, the Duke University Medical Center Library, the Department of Medicine, the Department of Pathology, and the Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina; and the Department of Obstetrics and Gynecology, Tufts University School of Medicine, Boston, Massachusetts.
Article Synopsis
- A systematic review and meta-analysis were conducted to assess alloimmunization rates in patients receiving red blood cells (RBCs) matched for standard ABO+D blood type versus those additionally matched for c, E, and Kell antigens (cEK).
- Among the 10 studies analyzed, involving 91,221 transfused patients, those receiving cEK-matched RBCs had a significantly lower alloimmunization rate of 1.9% compared to 6.2% for ABO+D-only matching.
- The findings suggest that implementing cEK matching protocols could reduce alloimmunization risks, particularly important for patients with reproductive potential under the age of 50, highlighting a need for routine testing in this demographic.
The role of erythrocytes and erythroid progenitor cells in tumors.
Open Life Sci
December 2022
Department of Oncology, The Eighth Medical Center, Chinese PLA (People's Liberation Army) General Hospital, Beijing 100071, China.
In the current research context of precision treatment of malignant tumors, the advantages of immunotherapy are unmatched by conventional antitumor therapy, which can prolong progression-free survival and overall survival. The search for new targets and novel combination therapies can improve the efficacy of immunotherapy and reduce adverse effects. Since current research targets for immunotherapy mainly focus on lymphocytes, little research has been done on erythrocytes.
View Article and Find Full Text PDFReduction of anti-K-mediated hemolytic disease of newborns after the introduction of a matched transfusion policy: A nation-wide policy change evaluation study in the Netherlands.
Transfusion
March 2021
Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Article Synopsis
- - The study investigates the impact of a K-matched transfusion policy implemented in the Netherlands since 2004, aimed at preventing maternal red blood cell antibodies, particularly anti-K, that can cause severe complications during pregnancy.
- - Data analyzed from over 36,000 pregnancies revealed a significant drop in the occurrence of anti-K antibodies from 67.9 to 20.2 per 100,000 pregnancies, highlighting a notable relative risk reduction in alloimmunization cases.
- - The findings suggest that this transfusion policy greatly reduces the number of pregnant women at risk for anti-K-related issues, demonstrating its effectiveness in preventing hemolytic disease in fetuses and newborns.
Type 1 Interferon Gene Signature Promotes RBC Alloimmunization in a Lupus Mouse Model.
Front Immunol
June 2021
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Red blood cell (RBC) transfusion exposes recipients to hundreds of unmatched minor RBC antigens. This exposure can lead to production of alloantibodies that promote clinically significant hemolytic events. Multiple studies have reported an increased frequency of RBC alloimmunization in patients with autoimmunity.
View Article and Find Full Text PDFDecrease in the Risk of Posttransplant Hepatocellular Carcinoma Recurrence After the Conversion to Prestorage Leukoreduction for Transfused Red Blood Cells.
Transplantation
March 2021
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Background: Prestorage leukoreduction has the advantage over poststorage leukoreduction in reducing leukocyte-derived molecules in red blood cells (RBC) unit, which induce immunomodulation. Our institution newly introduced prestorage leukoreduction, instead of conventional poststorage leukoreduction, for liver transplant recipients since March 2012. In this study, we aimed to evaluate the risk of posttransplant hepatocellular carcinoma (HCC) recurrence after the conversion of poststorage leukoreduction into prestorage leukoreduction for transfused allogeneic RBCs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!